Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saxagliptin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saxagliptin Anhydrous SCHEMBL988028 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL882684 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL15579932 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL2742680 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL15752149 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL12518855 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL23752173 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL8250350 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL17131050 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 | |
| Saxagliptin Anhydrous SCHEMBL17168 | 1.00 | DPP4 (1.00) | DPP4CYP3A4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973827-B2 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2021-04-01 | — | — | US | disclosed |
| US-20200323861-A1 | ANTIDIABETIC MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2020-10-15 | — | — | US | disclosed |
| US-20200069693-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2020-03-05 | — | — | US | disclosed |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2019-04-11 | — | — | US | disclosed |
| US-10034877-B2 | Treatment for diabetes in patients inappropriate for metformin therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-31 | — | — | US | disclosed |
| US-20170020868-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2017-01-26 | — | — | US | disclosed |
| WO-2005106011-A2 | PROCESS FOR PREPARING DIPEPTIDYL IV INHIBITORS AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020868-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 78/4885DPP8 5/4885 |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 78/4885DPP8 5/4885 |
| US-10034877-B2 | Treatment for diabetes in patients inappropriate for metformin therapy | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 78/4885DPP8 5/4885 |
| US-20200323861-A1 | ANTIDIABETIC MEDICATIONS | SLC5A1, SLC5A2, DPP4 | DPP4 3/4885CYP3A4 599/4885DPP8 14/4885 |
| US-10973827-B2 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 24/4885DPP8 5/4885 |
| US-20200069693-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 24/4885DPP8 5/4885 |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 78/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.